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Glossary of abbreviations 
 
AAV1 Adeno-Associated Virus 1 
ALS Amyotrophic Lateral Sclerosis 
ANOVA Analysis of Variance 
ER Endoplasmic Reticulum 
FACS Fluorescence-Activated Cell Sorting 
FUS Fused-in-Sarcoma 
GFP Green Fluorescent Protein 
iPSC Induced Pluripotent Stem Cells 
MEA Microelectrode Arrays 
SEM Standard Error of the Mean 
SOD1 Cu-Zn Superoxide Dismutase 1 
RFP Red Fluorescent Protein 
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Section 1: Introduction 
 
Amyotrophic Lateral Sclerosis - or Lou Gherig’s disease, as it is known in the United States in honor of 
the great baseball player who developed the disease in the 1930s - is a rapidly progressive, currently 
untreatable, and highly fatal neurodegenerative disease of the human motor nervous system involving 
both lower and upper motor neurons1. Descriptions of ALS cases have been found in the medical 
literature as early as 1824, but it was in the late 19th century that the famous French physician and 
neurobiologist Jean-Martin Charcot first reported on the relationship between the clinical signs of the 
disease and its associated autopsy findings3. Prevalence rates in Europe and North America have ranged 
between 2.7 to 7.4 people per 100,000 persons, with an incidence between 1.5  to 2.7 per 100,000 
persons/year4,5. ALS usually manifests in mid-life, with most cases diagnosed between the ages of 50 
and 606, although its incidence increases with every decade after 40 years old and peaks at age 744. 
The cause is unknown in a majority of cases of ALS, with 90 to 95 percent of patients presenting with 
sporadic forms of the disease, while only 5 to 10 percent suffering forms with a clear familial 
inheritance6. Several genes have been identified as causal in the familial form - as well as a minority of 
sporadic cases. The most commonly involved gene is C9orf72 - so called as a reference to the usual 
position of the “open reading frame” in chromosome nine -, which is responsible for 40 to 50 percent of 
cases of familial ALS as well as 10 percent of sporadic cases7. The exact pathogenic mechanism by which 
the C9orf72 gene mutation leads to the disease remains unclear, but some proposed pathways include 
loss of function; toxicity conferred by RNA sequences derived from C9orf72 genes containing an 
abnormally high number of the hexanucleotide GGGGCC repeats (normally <30 but as high as 700-1600 
in affected patients)8; and toxicity conferred by the creation of dipeptide repeat proteins. 
The second most commonly involved gene is the Cu-Zn superoxide dismutase 1 (SOD1) gene, which 
accounts for around 20 to 25 percent of hereditary cases2, along with 1 to 2 percent of sporadic cases6. 
Similar to C9orf72, the exact pathogenic effects of the SOD1 mutation remain unclear, but pathways 
proposed include aberrant redox activity and abnormal aggregation of mutant SOD1 protein in motor 
neurons2. What does appear clear is that the pathogenesis of the SOD1 gene mutation is not related to 
loss of function, as animal experiments involving deletion of the gene do not lead to the manifestation 
of the disease.  Another gene identified as causal in ALS is the fused-in-sarcoma gene (FUS), which gives 
rise to an RNA binding protein that may become mislocalized to the cytoplasm in mutant forms leading 
to its abnormal aggregation. 
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Several hypotheses exist to explain the relationship between the aforementioned genetic mutations -as 
well as others - and the clinical and pathologic manifestations of the disease, namely the observed early 
cell death of upper and lower motor neurons. The four leading hypotheses include: 1) oxidative damage 
(prompted by the discovery of the SOD1 mutation), 2) axonal dysfunction from neurofilamentous 
disorganization (supported by the finding of abnormal accumulation of neurofilaments as a pathological 
feature of many cases of sporadic and SOD1-mediated familial disease), 3) toxicity from intracellular 
aggregates and/or failure of protein folding or degradation (common in SOD1- and FUS-associated 
cases), and 4) excitotoxic death6.  
It was the latter hypothesis that we were interested in exploring. Under the excitotoxicity theory, some 
have posited that problems in the appropriate retrieval of the neurotransmitter glutamate from the 
synaptic cleft by astrocytes lead to increased post-synaptic motor neuron stimulation, increased levels 
of intracellular calcium, and eventually cell death6. Support for this theory arose from the discovery of 
large increases in the levels of glutamate in the cerebrospinal fluid of ALS patients and reduced 
astrocytic glutamate transport. What is particularly interesting is the fact that these abnormally 
increased levels are observed not only in familial cases, but also in up to 40 percent of sporadic cases. 
Nevertheless, nerve conduction studies evaluating axonal threshold (strength-duration time constant 
and recovery cycle times) in ALS patients have demonstrated increased axonal membrane excitability 
well away from any synapses9–12, and the degree of hyperactivity correlates with patient survival10. 
These findings bring the causal relationship between glutamate and excitotoxicity into question, and 
instead raise the possibility of intrinsic causes existing to explain this observed motor neuron 
hyperactivity.  
Studies of ALS have so far been limited by the availability of mouse models and/or viable cell lines6. 
Transgenic mice that overexpress the G93A mutation of the human SOD1 gene (hSOD1(G93A) mice) are 
one of the most commonly used and accepted animals models13. Studies using hSOD1(G93A) mice have 
indeed confirmed higher levels of baseline activity of diseased motor neurons, and have identified 
increased persistent sodium currents as causal, at least partly14. However, it remains unknown whether 
this increased neural activity is a common feature shared by other genetic causes of ALS such as those 
caused by C9orf72 or FUS mutations, and this is mainly due to the lack of availability of representative 
mouse models. 
The ability to derive motor neurons from human iPSCs obtained from both ALS patients as well as 
healthy controls has greatly facilitated the study of the electrophysiological properties of ALS neurons, 
as well as several other neurodegenerative disorders. As presented by Takahashi et al. in their 
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publication in 2007, iPSCs derived from human dermal fibroblasts treated with four transcription factors 
(OCT 3/4, SOX2, KLF4, and c-Myc) are similar to human embryonic stem cells in morphology, 
proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes, and 
telomerase activity15. Further advancements introduced by Dimos et al. in their publication in 2008, 
allowed for the differentiation of patient-derived iPSCs into ALS motor neurons and glia16. This 
technology has permitted for the generation of patient-specific ALS motor neurons, representing several 
disease-causing mutations. Though motor neurons obtained from patient and control-derived iPSCs 
have already been used to study the pathogenic mechanisms of ALS, these studies have so far been 
limited by a small number of cell lines, thus proving difficult to generalize across other cell lines and 
patients17. We overcame this limitation in this study by deriving cell lines from eight different ALS 
patients bearing three different ALS-causing mutations (SOD1 mutation, C9orf72 repeat expansions, and 
FUS mutation) and compared them to motor neurons derived from iPSCs originating from five healthy 
controls. We further used gene-targeted correction of the disease-causing SOD1 mutation to produce 
otherwise isogenic stem cells bearing wild-type SOD1 alleles18. This constituted the largest sample of ALS 
motor neurons studied to date. We began our exploration by characterizing the intrinsic neuronal 
activity of ALS motor neurons in comparison to controls utilizing MEA technology -which allows for the 
simultaneous detection of single-unit activity within a large population of cultured cells by a 64-
electrode array embedded directly within the culture well- and correlated it to cell life span for both ALS 
and control neurons. We then used whole-cell patch-clamp technology to explore the specific behavior 
of the different ion channels that control/affect neuronal firing, and determined that ALS-derived motor 
neurons have reduced delayed-rectifier voltage-gated potassium currents in comparison to controls. In 
all experiments, we ensured the blockade of both excitatory and inhibitory neurotransmitters in order to 
examine only the intrinsic properties of these neurons. We then reversed a disease-causing mutation 
using zinc fingers-based genetic targeting and ensured cell hyperactivity as well as cell life returned to 
baseline. Most importantly, we utilized the drug retigabine -a known activator of Kv7 delayed-rectifier 
potassium channels, and an FDA-approved drug for the treatment of epilepsy- to increase delayed-
rectifier potassium currents in order to reverse the previously measured cell hyperactivity, which led to 
an improvement in cell survival.  
The aforementioned reduction in hyperexcitability held true across all cell lines originating from patients 
with SOD1, C9orf72, and FUS mutations, thus raising the possibility of evaluating retigabine in a safety 
study in humans.  
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The work presented in this report has been previously published in the journal Cell Reports, on April 3, 
2014, as an article titled “Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-
Derived Motor Neurons”, primary authored by Brian Wainger, M.D., PhD et al.19 
Numa Perez, the author of this Scholarly Project Report, was a co-author of the aforementioned 
scientific journal article, and was directly responsible for conducting the experiments using MEAs, as 
well as analyzing the resulting data, to include writing all MATLAB code necessary to accomplish this 
task. His work directly resulted in Figures 1B-G, 3D, 4, and 5A of this report, with corresponding figures 
in the original journal article. 
All generation and molecular analysis of iPSC-derived motor neurons was conducted by members of the 
laboratory of Kevin Eggan, PhD, at the Harvard Department of Stem Cell & Regenerative Biology. All 
patch-clamp experiments were conducted by Cassidy Mellin and Brian Wainger, M.D., PhD, members at 
the time of the laboratory of Clifford Woolf, MB, BCh, PhD, at the FM Kirby Neurology Center, Boston 
Children’s Hospital. All statistical analysis was conducted by Brian Wainger, M.D. with the assistance of 
K. Kapur. All figures were modified from MATLAB originals and/or directly created by Brian Wainger, 
M.D., PhD, with the assistance of K. Wainger. 
 
Section 2: Methods 
 
iPSC Lines, Culture, and Motor Neuron Differentiation 
 
iPSC generation from patient fibroblasts obtained under institutional review board approval, 
characterization, and motor neuron differentiation were performed as described in Kiskinis et al. (2014), 
with iPSC line scoring as done previously20. For transfection of 18a and 39b lines with an Hb9::GFP 
reporter, a 1 kb Hb9 promoter fragment (gift from Hynek Wichterle) controlling the expression of 
myristoylated GFP was inserted into a donor plasmid specific for the AAVS1 locus (Sigma). Subsequently, 
2.5 million iPSCs were accutased and electroporated using the Neon transfection system (100 μl tip; 
1,600 V voltage, 20 ms width, 1 pulse; Life Technologies) with 2 μg of AAVS1 ZFN plasmid and 6 μg of 
modified AAVS1 donor plasmid. After nucleofection, cells were plated on matrigel with mTeSR1 in the 
presence of ROCK inhibitor. After 48 hr, puromycin selection was applied, and surviving clonal colonies 
were individually passaged and genomic DNA was extracted. PCR was used to confirm proper targeting 
of the cassette. Primer sequences are available upon request. Faithful expression of the reporter was 
verified using expression of the motor neuron marker Isl1. 
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iPSCs were maintained on culture dishes as described previously21 with modifications 18 in a 24 day 
protocol based on initial neuralization with SB431542 (10 μM, Sigma-Aldrich) and Dorsomorphin (1 μM, 
Stemgent), and motor neuron patterning with RA (Sigma) and a small smoothened Agonist 1.3 
(Calbiochem). FACS-purified neurons were grown on a confluent monolayer of primary cortical mouse 
glia prepared from P0–P2 mouse pups (as described in Boulting et al., 2011), which may increase firing 
rates compared to experiments without glia22). 
 
MEA Recording 
 
After 24 days of differentiation, equal numbers of control and ALS neurons were plated on poly-D-
lysine/laminin coated p515A probes (Alpha Med Scientific) or M768-GLx 12-well plates (Axion 
BioSystems) at typical densities of 40,000 to 80,000 cells/probe or well. All probes were visualized 
immediately before each recording session to confirm a full monolayer of cells. Initial experiments (11a, 
18a, 39b, and RB9d comparison) were performed as close as possible to the time of patch recordings (4 
weeks). However, because we wished to evaluate firing at a time point prior to significant motor neuron 
death18, we performed subsequent experiments (39b-Cor and 39b comparison and all later experiments) 
at day 14 after dissociation. 
 
Recordings from 64 extracellular electrodes were made using a Med64 (Alpha Med Scientific) or 
Maestro (Axion BioSystems) MEA recording amplifier with a head stage that maintained a temperature 
of 37°C. For Med64 recordings, data were sampled at 20 kHz, digitized, and analyzed by spike clustering 
and spike extraction algorithms using Mobius software (Alpha Med Scientific) with a 2 kHz 9-pole Bessel 
low pass filter, 10 μV action threshold detection limit, and 30% cluster similarity radius. These standard 
settings were maintained for all analyses. We confirmed that we obtained similar results across a wide 
range of action potential threshold and cluster similarity radius settings. Correlation analysis to detect 
and correct for clusters detected by multiple electrodes was performed using custom MATLAB software. 
Total action potential firing rates and mean neuronal firing frequencies were then determined and 
plotted. In order to record in larger replicates, we used the Axion Maestro MEA device, in a 12-well 
format with 64 extracellular electrodes in each well. For Maestro recordings, data were sampled at 12.5 
kHz, digitized, and analyzed using Axion Integrated Studio software (Axion BioSystems) with a 200 Hz 
high pass and 2.5 kHz low pass filter and an adaptive spike detection threshold set at 5.5 times the SD 
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for each electrode with 1 sec binning. These standard settings were maintained for all Axion MEA 
recording and analysis. 
 
For retigabine dose-response curves, action potential numbers during 1 min of recording in each 
concentration of retigabine were normalized to the initial action potential number during 1 min of 
recording in standard extracellular saline solution. The EC50 value was determined by fitting the mean 
normalized data values to the Hill equation, y = 1/((EC50/x)nH+1) where nH is the Hill coefficient. 
 
Patch Electrophysiology 
 
Whole-cell patch recordings were performed on iPSC-derived motor neurons identified by transduction 
with an Hb9::RFP lentivirus. Lentiviral transduction was typically performed 7 to 10 days before 
recording. Two large comparisons were performed, one consisting of 11a, 18a, 39b, and RB9d, and the 
second consisting of 39b-Cor and 39b. Each comparison was made from pooled data from multiple 
separate experiments, each consisting of synchronous and parallel iPSC culture and differentiation, 
embryoid body dissociation, plating, and maturation of control- and ALS-derived neurons. Equal 
numbers of control and ALS motor neurons were recorded from each experiment. Comparison of the 
original four lines (11a, 18a, 39b, and RB9d) was made using four separate parallel differentiation 
experiments, whereas comparison of the isogenic correction comparison (39b-Cor and 39b) was 
performed using three separate parallel differentiation experiments. 
 
For each experiment, neurons from control and ALS lines were dissociated after 24 days of 
differentiation and plated onto poly-d-lysine/laminin coated glass coverslips (20,000 to 40,000 
cells/coverslip) and allowed to mature for four weeks from start of differentiation. We chose four weeks 
as the best time point because this yielded the most homogeneous population of mature-appearing 
Hb9::RFP-positive motor neurons (at the requisite low cell density for patch clamp) with the most 
mature electrophysiological properties. Whole-cell current-clamp and voltage-clamp recordings were 
performed using a Multiclamp 700B (Molecular Devices) at room temperature (21°C–23°C). Data were 
sampled at 20 kHz and digitized with a Digidata 1440A A/D interface and recorded using pCLAMP 10 
software (Molecular Devices). Data were low-pass filtered at 2 kHz. Patch pipettes were pulled from 
borosilicate glass capillaries on a Sutter Instruments P-97 puller and had resistances of 2–4 MΩ. The 
pipette capacitance was reduced by wrapping the shank with Parafilm and compensated for using the 
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amplifier circuitry. Series resistance was typically 5–10 MΩ, always less than 15 MΩ, and compensated 
by at least 80%. Neurons were excluded from analysis if holding current at −80 mV exceeded 100 pA, 
input resistance was less than 250 or greater than 2000 MΩ, or spikes elicited from −65 mV had peaks 
below 0 mV. Resting membrane potential was determined by averaging for 20 s of recording, and 
afterward a small holding current (typically with amplitude less than 5 pA) was used to clamp the resting 
membrane potential as close as possible to −65 mV. Rheobase was measured by applying 1 sec steps in 
increments of 2.5 pA until an action potential was generated. Current ramps were elicited from an initial 
hyperpolarizing current of 10 pA for 1 sec followed by a 210 pA/sec depolarizing ramp of duration 1 sec. 
Spikes on the ramps were counted if the peak voltage exceeded −10 mV. Action potential properties 
were determined using custom-written analysis software in Igor Pro (Wavemetrics) with DataAccess 
(Bruxton) for importing the files. For voltage-clamp recordings, voltages were elicited by 100 ms 
depolarizing steps from a holding potential of −80 mV to test potentials ranging from −80 mV to 50 mV 
in 10 mV increments. For the latter gene correction experiments, the step length was increased to 200 
ms to assay delayed-rectifier currents after more complete decay of transient potassium currents. For 
retigabine patch applications, resting membrane potential was recorded immediately before and 10 sec 
after the application of 10 μM retigabine (in each case, membrane potential was an average of values 
sampled for 20 sec). For all patch experiments, series resistance was monitored by brief −5 pA 
hyperpolarizing steps during current clamp recordings and by 5 mV hyperpolarizing steps during voltage-
clamp recordings. Electrode drift was measured at the end of each recording and was typically 1–2 mV. 
The extracellular solution was sodium-based and contained 135 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM glucose, 10 mM HEPES 10 (pH 7.4). The intracellular solution was potassium based and 
contained 150 mM KCl, 2 mM MgCl2, 10 mM HEPES, 4 mM MgATP, 0.3 mM NaGTP, 10 mM Na2PhosCr, 1 
mM EGTA (pH 7.4). For isolation of delayed-rectifier potassium channels, 300 nM TTX and 100 μM CdCl2 
were used to block voltage-gated sodium channels and voltage- and calcium-activated potassium 
channels, respectively. For isolation of voltage-gated sodium currents, internal KCl was replaced by CsCl 
to block potassium currents and 100 μM CdCl2 was used to block calcium current. 
 
Cell Survival and ER Stress Assays 
 
Dissociated neurons (20,000) were plated on poly-D-lysine/laminin coated 8-well chamber slides (BD 
Biosciences) containing a confluent monolayer of primary cortical mouse glia21. For survival analysis, 
slides were fixed at 3 and 30 days, and cultures were stained for counting. The number of ISL-positive, 
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TUJ1-positive motor neurons (counter blinded to cell line identity) was normalized to the number on day 
3 for each line. Retigabine (1 μM) or vehicle control was added from day 15 onward. Eleven total 
experiments (control motor neurons) and nine total experiments (ALS motor neurons) were performed 
from the same four separate differentiations. ER stress experiments were performed as described in 
Kiskinis et al. (2014). In brief, in two separate independent biological replicates, 300 ng of RNA was used 
to generate cDNA, of which 2 μl and AmpliTaq Gold Polymerase (Applied Biosystems) were used for PCR 
amplification. The amounts of spliced and unspliced bands were quantified using Image J. Quantitative 
RT-PCR was performed in triplicate using the iSCRIPT kit (Bio-Rad) for cDNA synthesis and SYBR green 
(Bio-Rad) labeling followed by amplification using the iCycler system (Bio-Rad). 
 
Drugs 
 
Drugs included retigabine (Santa Cruz Biotechnology), bicuculline, strychnine, D-AP5, CNQX, flupirtine, 
TTX (all from Tocris Bioscience). CsCl and CdCl2 were from Sigma. 
  
Statistical Analysis 
 
p < 0.05 was considered statistically significant. Comparisons were made between control and ALS 
populations using t tests (two-tailed, unpaired)/ANOVA for continuous data and rank tests for 
nonparametric data (discrete measurements of number of spikes on ramps and Rheobase). For analysis 
of MEA firing over time, we used a mixed repeated-measures ANOVA model with fixed effects of cell 
line and time and random effects of individual replicate.  
 
For effect of retigabine on specific cells, paired tests were used. For effect of retigabine on survival, we 
fitted a linear regression model with effects of retigabine treatment, cell line, and their interaction. F-
tests for difference between ALS and control lines gave p = 0.0011, for effect of retigabine p = 3.8 × 10−4, 
and for effect modification p = 0.015. For ALS subjects, the effect of retigabine was an increase in cell 
count of 25.3% (SD 5.6, p = 6.4 × 10−5). The effect estimate for 39b was 16.9% (SD 12.9, p = 0.03) and 
for RB9d 39.9% (SD 11.3, p = 0.001). For control subjects, the effect of retigabine was an increase in cell 
count of 6.1% (SD 5.1, p = 0.23). For multiple genotype comparisons, one-way ANOVA after log 
transformation to normalize variance and post hoc Tukey tests were used to analyze multiple ALS 
variants. Error bars represent SEM unless indicated. 
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Section 3: Results 
 
Hyperexcitability of SOD1A4V/+-Derived Motor Neurons Using MEA Recordings 
 
We performed an initial set of electrophysiological phenotyping experiments using iPSC-derived motor 
neurons from two control subjects (11a, 18a) and two unrelated familial ALS patients (39b and RB9d) 
harboring the same aggressive SOD1A4V/+ mutation. All iPSC lines were generated via three-factor (OCT4, 
SOX2, KLF4) retroviral reprogramming, had a normal karyotype, and differentiated into motor neurons 
after robust neutralization based on dual SMAD inhibition23 and specification through exposure to 
retinoic acid and induction of sonic hedgehog signaling18,21 (Figure 1A).  
We recorded spontaneous firing of iPSC-derived motor neurons using extracellular MEAs, whereby the 
action potentials of individual neurons are detected by a grid of 64 extracellular electrodes embedded in 
each culture well. In four separate experiments, control and SOD1 ALS iPSC lines were cultured 
synchronously, differentiated into motor neurons in parallel, and plated in equal numbers on MEAs, 
which allowed recording of the spontaneous firing in hundreds of control and ALS patient derived 
neurons per differentiation after culturing for four weeks. We observed significantly more spontaneous 
action potentials in SOD1A4V/+ neurons relative to controls (p < 0.05, t test; Figures 1B and 1C). Action 
potentials were sorted by spike morphology and timing to derive clusters corresponding to individual 
neurons24 (Figure 2), , and a significantly higher average mean firing rate was observed in the SOD1A4V/+ 
neurons (p < 10-15, t test; Figures 1D and 1E). 
 
We performed two experiments to confirm that the activity detected by the MEAs resulted intrinsically 
from motor neurons only. Firstly, to test if differences observed in spontaneous action potential firing 
resulted from a larger number or a more active population of inhibitory neurons in control cultures, we 
applied GABAergic and glycinergic transmission blockers. The blockers did not increase action potential 
firing rates (p = 0.61, t test, for bicuculline; p = 0.24, t test, for strychnine), suggesting that activity of 
inhibitory neurons was minimal and that the heightened spontaneous firing in the MEA recordings of 
ALS-derived motor neurons reflected an intrinsic increase in excitability.  
 
Secondly, we inserted an Hb9::GFP (green fluorescent protein) reporter into the AAVS1 (adeno-
associated virus 1) locus for iPSCs 18a and 39b, allowing fluorescence-activated cell sorting (FACS) 
purification of GFP-positive motor neurons for recording on the arrays. We recorded every four days.  
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(A) Schematic of differentiation and recording. 
(B) Representative recordings from four out of 64 MEA electrodes in control (11a, 18a) and ALS (39b, RB9d)-derived neurons 
cultured for 28 days on the arrays. 
(C) Total action potential firing rate during 1 min of recording from MEAs (11a, n = 3; 18a, n = 3; control mean 6,510 ± 3,131 
spikes/min; 39b, n = 3; RB9d, n = 3; ALS mean 20,528 ± 5,069 spikes/min; p < 0.05, t test). 
(D) Mean firing rate histograms of individual neurons from MEAs in (B). 
(E) Average of mean firing rate for patient-derived neurons (11a, n = 381; 18a, n = 191; control mean 1.17 ± 0.04 Hz; 39b, n = 520; 
RB9d, n = 662; ALS mean 1.76 ± 0.05 Hz; p < 10-15, t test). 
(F) Total action potential firing rate during 1 min recordings from MEAs of FACS-sorted 18a Hb9::GFP and 39b Hb9::GFP motor 
neurons recorded every 4 days (repeated-measures ANOVA F-test p = 13104 for difference between lines; post hoc t tests with 
Bonferroni correction for multiple testing indicated as *p < 0.05 and **p < 0.01). 
(G) Total action potential firing rate during 1min of recording from MEAs cultured for 14 days on the arrays (39b-Cor, n = 4; mean 
775 ± 712 spikes/min; 39b, n = 4; 39b mean 6,278 ± 1,758 spikes/min; p = 0.01, t test). 
Error bars represent SEM. 
Figure 1: MEA Recording Reveals Increased Spontaneous Firing in ALS-Derived Neurons Compared to Control-Derived Neurons 
After insertion of the Hb9::GFP reporter into the AAVS1 locus for iPSC lines 18a and 39b, and FACS 
sorting of neurons, we recorded for four days and observed that 39b Hb9::GFP motor neurons 
consistently fired more action potentials than 18a Hb9::GFP motor neurons over the entire time course 
(mixed model ANOVA F-test p = 1x10-4 for difference between lines; post hoc t tests after Bonferroni 
correction for multiple comparisons for day 12, p = 0.0055; day 16, p = 0.0030; day 20, p = 0.0057; day 
24, p = 0.0029; day 28, p = 0.015; Figure 1F). Thus, the hyperexcitability must be due to motor neurons, 
because only Hb9-positive motor neurons were plated on the arrays. 
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Correction of the SOD1A4V/+ Mutation Eliminates the Hyperexcitability Phenotype 
 
To test if differences in action potential firing was a direct effect of the SOD1A4V/+ mutation, we took 
advantage of a gene-targeted derivative of the 39b iPSC line in which the A4V-encoding mutation had 
been corrected to a wild-type sequence by homologous recombination, 39b-SOD1+/+ (abbreviated 39b-
Cor) 18, and conducted MEA recordings on it. Because substantial cell death begins in ALS motor neurons 
after 15 days of neuronal maturation in our culture conditions 18, and because differences in motor 
neuron firing were detectable at this early time point (Figure 1F), we compared MEA recordings of 39b 
and isogenic-derived 39b-Cor motor neurons at 14 days, to avoid the possibility that increased firing 
reflected either neuronal death or select survival of hyperexcitable neurons. Although the baseline spike 
rate was lower at 14 than 28 days, patient-derived 39b neurons had a higher spontaneous firing rate 
than neurons in which the SOD1 mutation was corrected (p = 0.01 for total rate, t test; Figure 1G; 
average mean firing rate 1.30 ± 0.10 Hz for n = 122 39b-Cor and 1.50 ± 0.08 Hz for n = 208 39b; p < 0.05, 
t test). We conclude that the hyperexcitability phenotype reflects the presence of the disease-initiating 
mutation and precedes progressive motor neuron death. 
 
Confirmation of ALS Motor Neuron Hyperexcitability and Mechanistic Exploration Using 
Whole-Cell Patch Clamp 
 
To examine the electrophysiological properties of identified individual motor neurons, we transduced 
developing neurons with an Hb9::RFP (red fluorescent protein) lentiviral reporter and recorded only 
from RFP-positive motor neurons25 using whole-cell patch-clamp (Figure 2A). Both control- and SOD1 
ALS-derived motor neurons were electrically excitable. To quantify the degree of excitability, we assayed 
the number of action potentials fired in response to a slow ramp depolarization. The number of action 
potentials fired by ALS motor neurons was significantly greater than control motor neurons (p < 0.05, 
Mann-Whitney U test; Figure 2B, upper panels, Figure 2C, upper panel). Resting membrane potential, 
action potential threshold (Rheobase), and input resistance did not differ between ALS and control 
motor neurons, indicating that excitability differences were not due to differences in 
electrophysiological health or baseline capacity for action potential generation.  
 
When we compared motor neurons derived from 39b-Cor and 39b cell lines in three separate additional 
parallel experiments, we again observed a marked difference in the number of action potentials elicited 
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(A) An iPSC-derived motor neuron identified by Hb9::RFP lentiviral transduction (right) and during patch-clamp recording (left) 
after culture for 28 days. Scale bar, 20 mm. 
(B) Representative current clamp recordings during ramp depolarization from control and ALS patient-derived motor neurons 
(upper four panels); sample recordings from separate experiments comparing the isogenic correction of the 39b SOD1A4V/+ 
mutation (39b-Cor) and 39b (lower two panels). 
(C) Upper panel: average number of action potentials elicited by ramp depolarization from control (11a, n = 12; 18a, n = 11; 
control mean 2.5 ± 0.4) and ALS (39b, n = 13; RB9d, n = 12; ALS mean 4.2 ± 0.5) motor neurons obtained from four separate 
differentiations (p < 0.05, Mann-Whitney U test). Lower panel: separate experiments showing average number of action 
potentials during ramp depolarization from 39b-Cor (n = 17; mean 4.1 ± 0.5) and 39b (n = 19; mean 6.4 ± 0.9) motor neurons 
from three additional differentiations (p < 0.05, Mann-Whitney U test). 
(D) Sample voltage-clamp recordings from control and ALS-derived Hb9::RFP-positive motor neurons cultured for 28 days. 
(E) Average delayed-rectifier (DR) steady-state potassium current amplitude relative to peak sodium current amplitude in 
control (11a, n = 12; 18a, n = 11; control mean 0.88 ± 0.087) and ALS (39b, n = 13; RB9d, n = 12; ALS mean 0.44 ± 0.054) 
patient-derived motor neurons from four differentiations (p < 0.001, t test). 
(F) Experiments from three separate differentiations showing average delayed rectifier steady-state potassium current 
amplitude relative to peak sodium current amplitude in 39b-Cor (n = 18; mean 0.54 ± 0.061) and 39b (n = 19; mean 0.32 ± 
0.036; p < 0.005, t test). 
(G) Direct measurement of delayed-rectifier voltage-gated potassium current isolated by holding at -30 mV, stepping to a test-
potential of +40 mV for 2 s and normalizing steady state current amplitude to cell capacitance in 39b-Cor (n = 19; mean 42.6 ± 
4.3 pA/pF) and 39b (n = 18; mean 30.3 ± 3.1 pA/pF; p < 0.05, t test) derived motor neurons using cells from two additional 
separate differentiations. 
(H) Peak sodium current amplitude normalized to cell capacitance in 39b-Cor (n = 16; mean 400.4 ± 44.7 pA/pF) and 39b (n = 
15; mean 387.1 ± 50.5 pA/pF; p = 0.8, t test) derived motor neurons.  
Error bars represent SEM. 
Figure 2: ALS Patient-Derived Motor Neurons Are Hyperexcitable and Have Reduced Delayed-Rectifier Potassium Currents 
Compared to Control-Derived Motor Neurons 
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during ramp depolarization (p < 0.05, Mann-Whitney U test; Figure 2B, lower panels, Figure 2C, lower 
panel), demonstrating that the A4V mutation was essential for the phenotype. There was variability in 
the number of action potentials in motor neurons from the same line tested across multiple 
differentiations, but the increased number of action potentials in ALS motor neurons relative to control 
motor neurons was always preserved. This result underscores the importance of performing repeated 
parallel differentiations in which equal numbers of control and ALS motor neurons are analyzed from 
each differentiation.  
 
In addition to quantifying the electrical excitability of individual neurons, patch-clamp recording enables 
quantitative investigation of specific currents that determine excitability. To identify electrophysiological 
mechanisms responsible for differences in excitability, we performed voltage-clamp experiments using 
Hb9::RFP-positive motor neurons to examine current components. As an index of excitatory and 
inhibitory voltage-dependent ion channels, we quantified the ratio of outward delayed-rectifier 
potassium current to inward transient sodium current. In four repeated differentiations of motor 
neurons from control and SOD1A4V/+ iPSC lines, we observed that the ratio of delayed-rectifier potassium 
to transient sodium current was consistently smaller in the SOD1A4V/+ neurons (p < 0.001, t test; Figures 
2D and 2E).  The difference was driven primarily by the reduced delayed-rectifier potassium channel 
component, as the difference in steady-state potassium current amplitude normalized to individual cell 
capacitance between ALS subjects and healthy controls, was significant (control 137.0 ± 14.4 pA/pF, n = 
23, versus ALS 94.4 ± 10.7 pA/pF, n = 25; p < 0.05, t test), whereas the peak sodium current normalized 
to capacitance was not (control 190.3 ± 23.0 pA/pF, n = 21, versus ALS 237 ± 21.2 pA/pF, n = 23; p = 0.2, 
t test).  Because voltage-gated potassium channels repolarize the membrane potential back to negative 
values after an action potential, a decrease in such currents likely contributes to increased action 
potential firing in ALS motor neurons. 
 
Correction of the disease-causing SOD1A4V/+ mutation also increased the relative steady-state delayed-
rectifier potassium current amplitude, showing that this phenotypic difference specifically resulted from 
the A4V mutation (p < 0.005, t test; Figure 2F). We found a marked reduction in delayed-rectifier current 
magnitude in 39b compared to 39b-Cor motor neurons (p < 0.05, t test; Figure 2G) but no difference in 
sodium current peak amplitudes (p = 0.8, t test; Figure 2H). Thus, correction of the deficit in delayed-
rectifier potassium current in 39b-Cor motor neurons may enable repolarization of the membrane 
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potential back to normal hyperpolarized values and reduction of excitability to levels in wild-type motor 
neurons. 
 
Retigabine Blocks Motor Neuron Hyperexcitability and Increases in Vitro Survival of 
SOD1A4V/+ ALS Motor Neurons 
 
Motor neurons express many types of voltage-activated potassium channels and pharmacological 
dissection and quantification into distinct components is challenging. Regardless of which currents 
produce the hyperexcitability in diseased motor neurons, Kv7 (KCNQ) channels are attractive targets for 
correcting this hyperexcitability because of their activation at subthreshold voltages and subsequent 
powerful control of excitability26. Given this and the reduced delayed-rectifier potassium currents in 
ALS-derived motor neurons, we hypothesized that retigabine, a specific activator of subthreshold Kv7 
currents and clinically approved anticonvulsant27, might block hyperexcitability in the SOD1A4V/+ motor 
neurons. In whole-cell patch clamp, retigabine significantly increased the minimal current step necessary 
for action potential generation (Rheobase) by 3.6 ± 2.4 pA (p < 0.05, Wilcoxon signed rank test; Figure 
3A). Retigabine also stopped spontaneous firing of Hb9::RFP-positive motor neurons and hyperpolarized 
the resting membrane potential by 6.0 ± 2.2 mV (p = 0.001, t test; Figure 3B). Because these 
experiments were performed with blockers of glutamatergic, GABAergic, and glycinergic receptors, 
retigabine must have a direct effect on motor neuron excitability. We used MEA recordings to 
determine a dose-response for inhibition of spontaneous firing by retigabine of SOD1A4V/+ ALS-derived 
neurons. Retigabine suppressed ALS neuron spontaneous firing with an EC50 of 1.5 mM (Figure 3C), a 
concentration consistent with its pharmacological activity as an antiepileptic agent and similar to its 
EC50 for Kv7 channels28. In line with this finding, analysis of RNA sequencing (RNA-seq) data from FACS-
sorted motor neurons18 confirm expression of Kv7 channels. 
To evaluate the possibility that hyperexcitability is an upstream modulator of motor neuron 
degeneration in ALS, we tested if retigabine affects the survival of control and SOD1A4V/+ motor neurons 
over 30 days in culture. As observed by Kiskinis et al. under basal conditions, the loss of SOD1A4V/+ motor 
neurons was greater than SOD1+/+ control motor neurons18. Two weeks of treatment with retigabine (1 
mM) increased the number of ALS motor neurons in vitro by 25% (p < 10-4, t test; Figure 3D) to levels 
found in controls. 
To investigate how retigabine increases the survival of SOD1A4V/+ ALS motor neurons, we determined 
whether it affects pathways suspected to contribute to motor neuron death in ALS7. We chose to look at 
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Figure 3: Retigabine Reduces Motor Neuron Excitability 
and Increases Survival 
(A) Rheobase measurements in a 39b Hb9::RFP-
positive ALS-derived motor neuron in whole-cell patch 
clamp before (left) and after (right) the application of 
10 mM retigabine (baseline rheobase 4.8 ± 1.5 pA 
versus post-retigabine rheobase 8.4 ± 2.2 pA; n = 11; p 
< 0.05, Wilcoxon signed rank test). 
(B) Representative current clamp recording showing 
effect of 10 mM retigabine on membrane voltage and 
spontaneous firing (baseline Vm -60.4 ± 2.9 mV versus 
post-retigabine Vm -66.3 ± 3.6 mV, n = 11; p = 0.001, t 
test). In (A) and (B), CNQX (15 mM), D-AP5 (20 mM), 
bicuculline (25 mM), and strychnine (2.5 mM) were 
added to the external solution. 
(C) Dose-response curve for retigabine on suppression 
of spontaneous action potentials in MEA recording 
and Hill plot fit of mean data from 39b (n = 4) and 
RB9d (n = 4) with EC50 1.5 ± 0.8 mM. 
(D) Effect of vehicle (open circles) and 1mM retigabine 
(filled circles) treatment from days 14–28 of culture on 
the survival of Islet-positive, Tuj1-positive motor 
neurons measured at day 30 (total control n = 11; 
total ALS n = 9; F-test for effect of retigabine on all 
cells p = 3.8 3 10-4; effect of retigabine in ALS motor 
neurons, red, 25.3% (SD 5.6; t test p = 6.4 3 10-5); 
effect of retigabine in control motor neurons, black, 
6.1% (SD 5.1, p = 0.23). Cell counts are from individual 
wells for four separate differentiations.  
Error bars represent SEM. 
endoplasmic reticulum (ER) stress because of the demonstration that ER stress pathways are activated 
in SOD1A4V/+ ALS compared to SOD1+/+ motor neurons18. After two weeks of treatment with retigabine (1 
mM), XBP1 splicing was markedly decreased in retigabine compared to vehicle-treated 39b SOD1A4V/+ 
ALS motor neurons. In addition to reduced XBP1 splicing, we observed a decrease in PUMA and increase 
in EIF2B3 transcript levels, consistent with downregulation of ER stress in response to retigabine 
treatment.  
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Figure 4: Hyperexcitability of C9orf72 Repeat Expansion-Derived 
Motor Neurons 
(A) Representative recordings from four/64 MEA electrodes 
recorded from control (11a, 18a) and C9orf72 expansion ALS-
derived neurons (19f, RB8b) cultured for 14 days. 
(B) Total action potential firing rate during 1 min of recording 
from MEAs (11a, n = 1; 18a, n = 3; control mean 4,752 ± 2,786 
spikes/min; 19f, n = 3; RB8b, n = 3; ALS mean 20,022 ± 3,775 
spikes/min; p < 0.05, t test). 
(C) Average of mean firing rate for control and C9orf72-derived 
neurons (11a, n = 82; 18a, n = 203; control mean 1.11 ± 0.06 
Hz; 19f, n = 407; RB9d, n = 929; ALS mean 1.50 ± 0.04; p < 10-5, 
t test).  
Error bars represent SEM. 
Motor Neuron Hyperexcitability Is Present in Distinct ALS Forms and Is Blocked by Kv7 
Activators 
 
In order to investigate whether motor neuron hyperexcitability generalized to additional ALS variants, 
we performed MEA recordings of motor neurons derived from iPSC lines made from two unrelated 
familial ALS patients with C9orf72 hexanucleotide repeat expansion (19f and RB8b)18, which is 
responsible for 40 to 50 percent of familial ALS and approximately 10 percent of sporadic cases7.Motor 
neurons derived from patients 19f and RB8b, bearing the C9orf72 repeat expansion mutation, also 
showed significant hyperexcitability compared to controls in both total firing rate (p < 0.05, t test; 
Figures 4A and 4B) and average mean neuronal firing rate (p < 10-5, t test; Figure 4C). 
 
 
 
We reasoned that comparing neuronal firing properties of a large group of ALS patient and control-
derived motor neurons would help evaluate the robustness of the motor neuron hyperexcitability and, 
together with the A4V gene correction experiments, eliminate artifacts due to cell line variation. SOD1-
derived motor neurons (four lines from four unrelated subjects harboring three different mutations), 
C9orf72-derived motor neurons (two lines from two unrelated subjects), FUS-derived motor neurons 
Page 19 of 29 
 
(A) Multielectrode array recordings of motor neurons derived from control (11a, n = 8; 15b, n = 2; 17a, n = 5; 18a, n = 7; 
18b, n = 10; 20b, n = 6), SOD1 (25b, D90A, n = 3; 27d, G85S, n = 7; 39b, A4V, n = 3; RB9d, A4V, n = 7), C9orf72 expansion 
(19f, n = 2; RB8B, n = 13) and FUS (MGH5b, frameshift mutation at residue 511, n = 10; RB21, H517Q, n = 4) subjects 
cultured for 14 days. ANOVA, p < 10-7; Tukey’s post hoc tests for control versus SOD1 p < 0.01, control versus C9orf72 p < 
0.01, control versus FUS p < 0.05. For subject 18, motor neurons from two different iPSC lines were recorded. Error bars are 
95% confidence interval. 
(B) Dose-response curve for retigabine on suppression of spontaneous action potentials in MEA recording and Hill plot fit of 
mean data from SOD1 (n = 10; EC50 1.9 ± 0.5 mM), C9orf72 (n = 9; EC50 2.6 ± 0.8 mM) and FUS (n = 4; EC50 1.9 ± 1.1 mM). 
(C) Dose-response curve for flupirtine on suppression of spontaneous action potentials in MEA recording and Hill plot fit of 
mean data from SOD1 (n = 5; EC50 9.8 mM), C9orf72 (n = 4; EC50 19.4 mM) and FUS (n = 2; EC50 15 mM).  
Error bars for (B) and (C) represent SEM. 
(two lines from two unrelated subjects harboring two different mutations) were all hyperexcitable 
relative to motor neurons derived from six iPSC lines made from five individual healthy controls 
(ANOVA, p < 10-7; Tukey’s post hoc tests for control versus SOD1 p < 0.01, control versus C9orf72 p < 
0.01, control versus FUS p < 0.05; Figure 5A). Furthermore, spontaneous action potential firing in the 
ALS variant-derived motor neurons was uniformly blocked by retigabine (Figure 5B). Consistent with an 
on-target effect of retigabine, we found that a chemically distinct but less potent Kv7 current enhancer, 
flupirtine26, also blocked spontaneous motor neuron firing (Figure 5C). These results demonstrate the 
broad relevance of motor neuron hyperexcitability for familial ALS and its sensitivity to Kv7 agonists 
across iPSC lines, patients and genotypic etiologies. 
 
 Figure 5: Motor Neuron Hyperexcitability and Block by Retigabine Are Broad Properties of ALS Variants 
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We ultimately analyzed four lines from four unrelated subjects (25b, 27d, 39b, RB8da) harboring three 
different mutations of the SOD1 gene, two lines from two unrelated subjects (19f and RB8b) bearing the 
C9orf72 repeat expansion mutation, and two lines from two unrelated subjects (MGH5b, RB21) bearing 
two different mutations. 
 
Section 4: Discussion 
 
Neurons derived from patient iPSCs can be used to investigate physiologic changes in specific neural 
subtypes relevant to neurodegeneration and reveal important disease mechanisms and candidate 
therapeutics. We found consistent hyperexcitability in motor neurons from a broad group of familial ALS 
patients, whose disease-causing mutations collectively span the majority of familial ALS cases. 
Differential excitability of particular motor neurons has been proposed to explain the selective 
vulnerability of specific motor neuron pools in ALS, and our data provide a possible mechanistic basis for 
this hypothesis29,30. 
Motor neuron hyperexcitability may contribute, therefore, to motor neuron death, although 
connections between hyperexcitability and motor neuron death in other ALS variants will now require 
further investigation. Our results are consistent with multiple studies exploring excitotoxicity6,31 but, 
potentially, not with two recent studies. One postulated that increased excitability in the hSOD1(G93A) 
mouse model may be a compensatory mechanism32. However, systemically administered glutamatergic 
and cholinergic modulators may affect multiple neuronal types, making it difficult to assess how the 
findings relate to motor neuron excitability, which was not measured. A second study found decreased 
numbers of elicited spikes in iPSC-derived motor neurons from ALS patients with C9orf72 repeat 
expansion compared to controls33. The differences in spike count here may reflect the longer 
differentiation time (66–79 days), differences in surviving neuronal populations or alterations in resting 
membrane potential in C9orf72 compared to control neurons. For example, the more depolarized 
resting potential in C9orf72 expansion-derived neurons could result in greater sodium channel 
inactivation and reduced capacity for generation of multiple action potentials; indeed, depolarization 
induced action potential blockade may be a late phase of progressive hyperexcitability. Mouse 
hSOD1(G93A) motor neurons show hyperexcitability even at an embryonic age13,34,35, and 
neurophysiological studies reveal increased excitability in C9orf72 repeat expansion subjects36 in 
addition to other familial and sporadic ALS cases12,14,37,38. 
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Previously, attention has been focused on persistent sodium currents as a mechanism of motor neuron 
hyperexcitability14,39, and riluzole, the only approved drug for ALS, blocks this current40. Our findings 
suggest an additional important role of voltage-activated potassium channels. 
Channel compartmentalization may differ between in vivo and cultured-neuron systems; however, a 
recent immunohistochemical study of human spinal cords found decreased protein levels of a delayed-
rectifier potassium channel selectively in the ventral roots of sporadic ALS but not control subjects41. 
Mutations in voltage-gated potassium channels cause other neurodegenerative diseases42, and 
oxidation of potassium channels (with consequent modulation of voltage-dependence and kinetics of 
channel gating) has been suggested as a broad mechanism of aging and neurodegeneration43. DPP6, 
which is involved with in-trafficking Kv4 voltage-gated potassium channels in CA1 hippocampal neurons, 
is linked to ALS44,45. Hypermethylation and downregulation of potassium channel genes were observed 
in epigenetic analyses of postmortem ALS patient spinal cords46. 
Both enhanced persistent sodium and reduced potassium currents could converge to produce 
hyperexcitability, and both may offer complementary pharmacological targets to control it. 
Although our study evaluated hyperexcitability as an innate or autonomous property of motor neurons, 
differences in excitability may also reflect interactions between motor neurons and glia or Schwann 
cells31. Hyperexcitability has also been observed in motor neurons from a mouse model of spinal 
muscular atrophy47, and there is evidence for both cell autonomous48 and nonautonomous49 modulation 
of excitability. 
Interestingly, spinal muscular atrophy has also been linked to DPP6, raising the possibility of potassium 
channel contributions50. 
The pathways connecting disease-causing mutations and decreased potassium channel function, as well 
as hyperexcitability and motor neuron death continue to require further clarification. Calcium overload 
through voltage-gated calcium channels51 and activation of ER stress30 are possibilities. The finding that 
decreasing motor neuron activity reduces ER stress suggests that hyperexcitability may be upstream of 
the unfolded protein response, explaining at least partially, how hyperexcitability may contribute to 
motor neuron death in ALS. Because ER stress modifiers increase motor neuron activity, a vicious cycle 
may result in ALS from reciprocal positive feedback between hyperactivity and ER stress18. 
Despite the asymptomatic early decades typical of ALS patients, we observed a disease-specific 
phenotype in iPSC-derived neurons cultured for only weeks. That this property manifests so quickly in 
culture may reflect the absence of supporting cells and the inhibitory circuitry normally present in vivo. 
Identification of a screenable electrophysiological phenotype that contributes to motor neuron death 
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and manifests quickly could facilitate investigation of ALS pathophysiology and identification or 
validation of therapeutics for individual patients. Furthermore, the phenotype may offer a personalized 
medicine approach to treatment, using response of stem cell-derived neurons as a guide for individual 
patient treatment selection; this strategy will require motor neurons derived from large cohorts of 
patients for validation. Studies of motor neuron excitability can now be expanded to determine whether 
all forms of ALS converge onto a single mechanistic pathway. More generally, our study illustrates the 
potential for using iPSCs differentiated into specific disease-relevant cell types to identify disease 
phenotypes, novel biomarkers, and potential treatments.  
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